Piscataway, NJ, February 1, 2019 – Legend Biotech USA, Inc (“Legend”) announced today that the company has recently joined the American Society for Blood and Marrow Transplantation (ASBMT™) Corporate Council. Representatives from Legend plan to actively participate in ASBMT Corporate Council forums. Participation in the ASBMT Corporate Council provides Legend Biotech with the opportunity to […]

San Diego, CA, December 3, 2018 – Legend Biotech reported updated data on the LEGEND-2 Phase 1/2 open label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory (R/R) multiple myeloma. The findings, featured in an oral presentation at the 2018 American […]

Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen.Piscataway, NJ (May 30, 2018) – Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration (FDA) has authorized its development partner, Janssen Biotech, Inc. (“Janssen”), to commence a Phase 1b/2 […]

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the […]